Different responses of repetitive behaviours in juvenile and young adult mice to Δ
2,5-dimethoxy-4-iodoamphetamine (DOI)
Tourette syndrome
motor tic
premonitory urge
side effect
tic disorder
Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD)
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
02
07
2020
revised:
20
10
2020
accepted:
22
10
2020
pubmed:
31
10
2020
medline:
22
6
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
Medicinal cannabis is in increasing use by patients with Tourette syndrome, a neuropsychiatric disorder that affects about 1% of the general population and has a childhood onset. However, the pharmacological effects of Δ The administration of 2,5-dimethoxy-4-iodoamphetamine (DOI) increases head twitch response (HTR) and ear scratch response (ESR) and has been proposed as an animal model useful to respectively study motor tics and premonitory urges associated with tic disorders. Comparing the potency of Δ Δ
Sections du résumé
BACKGROUND AND PURPOSE
Medicinal cannabis is in increasing use by patients with Tourette syndrome, a neuropsychiatric disorder that affects about 1% of the general population and has a childhood onset. However, the pharmacological effects of Δ
EXPERIMENTAL APPROACH
The administration of 2,5-dimethoxy-4-iodoamphetamine (DOI) increases head twitch response (HTR) and ear scratch response (ESR) and has been proposed as an animal model useful to respectively study motor tics and premonitory urges associated with tic disorders.
KEY RESULTS
Comparing the potency of Δ
CONCLUSION AND IMPLICATIONS
Δ
Substances chimiques
Medical Marijuana
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
614-625Subventions
Organisme : Tourette Association of America: Research Grant Award to SAG & PM
Organisme : University of Aberdeen: The Elphinstone Scholarship for Ph.D. students
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Abi-Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017). Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 29(4), 391-400. https://doi.org/10.1176/appi.neuropsych.16110310
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., … Collaborators, C. (2019). The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176(S1), S21-S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Anavi-Goffer, S., & Mulder, J. (2009). The polarised life of the endocannabinoid system in CNS development. Chembiochem, 10(10), 1591-1598. https://doi.org/10.1002/cbic.200800827
Artukoglu, B. B., & Bloch, M. H. (2019). The potential of cannabinoid-based treatments in Tourette syndrome. CNS Drugs, 33(5), 417-430. https://doi.org/10.1007/s40263-019-00627-1
Augustine, F., & Singer, H. S. (2019). Merging the pathophysiology and pharmacotherapy of tics. Tremor and Other Hyperkinetic Movements (N Y), 8, 595. https://doi.org/10.7916/D8H14JTX
Bacqué-Cazenave, J., Bharatiya, R., Barrière, G., Delbecque, J. P., Bouguiyoud, N., Di Giovanni, G., … De Deurwaerdère, P. (2020). Serotonin in animal cognition and behavior. International Journal of Molecular Sciences, 21(5), 1649. https://doi.org/10.3390/ijms21051649
Canal, C. E., Booth, R. G., & Morgan, D. (2013). Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology, 70, 112-121. https://doi.org/10.1016/j.neuropharm.2013.01.007
Canal, C. E., & Morgan, D. (2012). Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: A comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Testing and Analysis, 4(7-8), 556-576. https://doi.org/10.1002/dta.1333
Canal, C. E., Olaghere da Silva, U. B., Gresch, P. J., Watt, E. E., Sanders-Bush, E., & Airey, D. C. (2010). The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology, 209(2), 163-174. https://doi.org/10.1007/s00213-010-1784-0
Cavanna, A. E., Black, K. J., Hallett, M., & Voon, V. (2017). Neurobiology of the premonitory urge in Tourette's syndrome: Pathophysiology and treatment implications. The Journal of Neuropsychiatry and Clinical Neurosciences, 29(2), 95-104. https://doi.org/10.1176/appi.neuropsych.16070141
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., … Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology., 175, 987-993.
Darmani, N. A. (2001). Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice. Pharmacology, Biochemistry, and Behavior, 68(2), 311-317. doi: S0091-3057(00)00477-9 [pii]
Darmani, N. A., Janoyan, J. J., Kumar, N., & Crim, J. L. (2003). Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacology Biochemistry and Behavior, 75(4), 777-787. https://doi.org/10.1016/s0091-3057(03)00150-3
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., … Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479-1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
Dursun, S. M., & Handley, S. L. (1996). Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. Psychopharmacology, 128(2), 198-205. https://doi.org/10.1007/s002130050125
Egashira, N., Koushi, E., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2007). 2,5-Dimethoxy-4-iodoamphetamine (DOI) inhibits ∆9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Journal of Pharmacological Sciences, 105(4), 361-366. https://doi.org/10.1254/jphs.fp0071247
Egashira, N., Okuno, R., Shirakawa, A., Nagao, M., Mishima, K., Iwasaki, K., … Fujiwara, M. (2012). Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice. Biological & Pharmaceutical Bulletin, 35(3), 376-379. https://doi.org/10.1248/bpb.35.376
Fernandez-Ruiz, J., Sagredo, O., Pazos, M. R., Garcia, C., Pertwee, R., Mechoulam, R., & Martinez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323-333. https://doi.org/10.1111/j.1365-2125.2012.04341.x
Greydanus, D. E., & Tullio, J. (2020). Tourette's disorder in children and adolescents. Translational Pediatrics, 9(Suppl 1), S94-s103. https://doi.org/10.21037/tp.2019.09.11
Hasan, A., Rothenberger, A., Munchau, A., Wobrock, T., Falkai, P., & Roessner, V. (2010). Oral ∆9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report. Journal of Clinical Psychopharmacology, 30(2), 190-192. https://doi.org/10.1097/JCP.0b013e3181d236ec
Hawkins, M. F., Uzelac, S. M., Baumeister, A. A., Hearn, J. K., Broussard, J. I., & Guillot, T. S. (2002). Behavioral responses to stress following central and peripheral injection of the 5-HT2 agonist DOI. Pharmacology, Biochemistry, and Behavior, 73(3), 537-544. https://doi.org/10.1016/S0091-3057(02)00822-5
Hines, L. A., Freeman, T. P., Gage, S. H., Zammit, S., Hickman, M., Cannon, M., … Heron, J. (2020). Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiatry, 77, 1044-1051. https://doi.org/10.1001/jamapsychiatry.2020.1035
Jakubovski, E., & Muller-Vahl, K. (2017). Speechlessness in Gilles de la Tourette syndrome: Cannabis-based medicines improve severe vocal blocking tics in two patients. International Journal of Molecular Sciences, 18(8). https://doi.org/10.3390/ijms18081739
Janoyan, J. J., Crim, J. L., & Darmani, N. A. (2002). Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by Δ9-THC and other cannabinoids. Pharmacology, Biochemistry, and Behavior, 71(1-2), 155-162. https://doi.org/10.1016/S0091-3057(01)00647-5
Kanaan, A. S., Jakubovski, E., & Muller-Vahl, K. (2017). Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sciences, 7(5), 47. https://doi.org/10.3390/brainsci7050047
Klimkeit, E., Rinehart, N., May, T., & Bradshaw, J. (2017). Neurodevelopmental disorders. In S. R. Quah (Ed.), International encyclopedia of public health (second edition) (pp. 223-230). Oxford: Academic Press.
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790-4805. https://doi.org/10.1111/bph.13250
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., … Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 3611-3616. https://doi.org/10.1111/bph.15178
McGrath, J. C., & Lilley, E. (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP. British Journal of Pharmacology., 172, 3189-3193.
McNaught, K. S. P., & Mink, J. W. (2011). Advances in understanding and treatment of Tourette syndrome. Nature Reviews Neurology, 7(12), 667-676. https://doi.org/10.1038/nrneurol.2011.167
Milosev, L. M., Psathakis, N., Szejko, N., Jakubovski, E., & Muller-Vahl, K. R. (2019). Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: Results from a retrospective analysis and online survey. Cannabis and Cannabinoid Research, 4(4), 265-274. https://doi.org/10.1089/can.2018.0050
Muller-Vahl, K. R., Bindila, L., Lutz, B., Musshoff, F., Skripuletz, T., Baumgaertel, C., & Suhs, K. W. (2020). Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology, 45, 1323-1329. https://doi.org/10.1038/s41386-020-0671-6
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. The Journal of Clinical Psychiatry, 64(4), 459-465. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12716250
Navarro, M., Fernandez-Ruiz, J. J., De Miguel, R., Hernandez, M. L., Cebeira, M., & Ramos, J. A. (1993). Motor disturbances induced by an acute dose of Δ9-tetrahydrocannabinol: Possible involvement of nigrostriatal dopaminergic alterations. Pharmacology, Biochemistry, and Behavior, 45(2), 291-298. https://doi.org/10.1016/0091-3057(93)90241-k
Nespoli, E., Rizzo, F., Boeckers, T. M., Hengerer, B., & Ludolph, A. G. (2016). Addressing the complexity of Tourette's syndrome through the use of animal models. Frontiers in Neuroscience, 10, 133. https://doi.org/10.3389/fnins.2016.00133
Paramlall, M., & Tyagi, H. (2020). 34 case report of sertraline exacerbation of tics in Tourette's with OCD. Journal of Neurology, Neurosurgery, and Psychiatry, 91(8), e22. https://doi.org/10.1136/jnnp-2020-BNPA.51
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., … Ross, R. A. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacological Reviews, 62(4), 588-631. https://doi.org/10.1124/pr.110.003004 62/4/588 [pii]
Pichler, E. M., Kawohl, W., Seifritz, E., & Roser, P. (2019). Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. International Journal of Psychiatry in Medicine, 54(2), 150-156. https://doi.org/10.1177/0091217418791455
Rock, E. M., Bolognini, D., Limebeer, C. L., Cascio, M. G., Anavi-Goffer, S., Fletcher, P. J., … Parker, L. A. (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. British Journal of Pharmacology, 165(8), 2620-2634. https://doi.org/10.1111/j.1476-5381.2011.01621.x
Rojas-Corrales, M. O., Gibert-Rahola, J., & Mico, J. A. (2007). Role of atypical opiates in OCD. Experimental approach through the study of 5-HT2A/C receptor-mediated behavior. Psychopharmacology, 190(2), 221-231. https://doi.org/10.1007/s00213-006-0619-5
Rua, A., & Damásio, J. (2014). Tics induced by sertraline: Case report and literature review. Movement Disorders Clinical Practice, 1(3), 243-244. https://doi.org/10.1002/mdc3.12044
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research, 30(8), 1037-1043. https://doi.org/10.1007/s11064-005-6978-1
Sano, K., Mishima, K., Koushi, E., Orito, K., Egashira, N., Irie, K., … Fujiwara, M. (2008). Δ9-Tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience, 151(2), 320-328. https://doi.org/10.1016/j.neuroscience.2007.10.026
Taylor, J. L., Rajbhandari, A. K., Berridge, K. C., & Aldridge, J. W. (2010). Dopamine receptor modulation of repetitive grooming actions in the rat: Potential relevance for Tourette syndrome. Brain Research, 1322, 92-101. https://doi.org/10.1016/j.brainres.2010.01.052
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British Journal of Pharmacology, 150(5), 613-623. https://doi.org/10.1038/sj.bjp.0707133
Tikhonova, M. A., Kulikov, V. A., & Kulikov, A. V. (2011). Effects of LPS and serotonergic drugs on hygienic behavior in mice. Pharmacology, Biochemistry, and Behavior, 98(3), 392-397. https://doi.org/10.1016/j.pbb.2011.02.005
Trainor, D., Evans, L., & Bird, R. (2016). Severe motor and vocal tics controlled with Sativex®. Australasian Psychiatry, 24(6), 541-544. https://doi.org/10.1177/1039856216663737
Varvel, S. A., Bridgen, D. T., Tao, Q., Thomas, B. F., Martin, B. R., & Lichtman, A. H. (2005). Δ9-Tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. The Journal of Pharmacology and Experimental Therapeutics, 314(1), 329-337. https://doi.org/10.1124/jpet.104.080739
Wettstein, J. G., Host, M., & Hitchcock, J. M. (1999). Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI). Progress in Neuro-Psychopharmacology & Biological Psychiatry, 23(3), 533-544. https://doi.org/10.1016/s0278-5846(99)00014-7
Winslow, J. T., & Insel, T. R. (1991). Serotonergic modulation of the rat pup ultrasonic isolation call: Studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists. Psychopharmacology, 105(4), 513-520. https://doi.org/10.1007/BF02244372
Wong, D. F., Brasic, J. R., Singer, H. S., Schretlen, D. J., Kuwabara, H., Zhou, Y., … Grace, A. A. (2008). Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: Clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology, 33(6), 1239-1251. https://doi.org/10.1038/sj.npp.1301528
Wu, W.-H., & Cooper, R. L. (2012). Serotonin and synaptic transmission at invertebrate neuromuscular junctions. Experimental Neurobiology, 21(3), 101-112. https://doi.org/10.5607/en.2012.21.3.101
Yang, K. H., Galadari, S., Isaev, D., Petroianu, G., Shippenberg, T. S., & Oz, M. (2010). The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. The Journal of Pharmacology and Experimental Therapeutics, 333(2), 547-554. https://doi.org/10.1124/jpet.109.162594